Aiming at amyloid All eyes, however, are trained on a passive immune therapy that leaves both secretase enzymes alone and goes after amyloid-ß directly. Two candidates, Eli Lilly's solanezumab and Janssen and Pfizer's bapineuzumab (originally developed by the Dublin-based company Elan), are monoclonal antibodies that work with the immune system, binding to amyloid-ß and helping to clear accumulated amyloid-ß peptides in the brain. Both are being tested in phase III trials on thousands of participants with mild-to-moderate Alzheimer's disease (see 'Chasing the dream', page S18).
But some worry that researchers are spending too much time and resources on something that might never pan out. “I think amyloid-ß is proving to be a very intractable target,” says Cummings. “The great danger to the field is that if bapineuzumab fails, some pharmaceutical companies will decide that Alzheimer's disease is too tough a target to yield stockholder value and will redirect their resources toward more tractable diseases.”
I hope bapi gets approved. 5% royalites (approx)to I>L>N>S>, that's 50 million for every billion. That will finance their other drugs that are better than bapi.
Market Data 
Markets 
AI
